Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” ...

RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...

( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects ...

Disc Medicine stock is hit by an FDA CRL for bitopertin. Learn key trial risks, cash runway, and why APOLLO Phase 3 results ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

This study provides a useful contribution to understanding how wearable augmentation devices interact with human proprioception, using a longitudinal design over a single session. Results demonstrate ...